financetom
Business
financetom
/
Business
/
BRP Q1 Profit, Revenue Fall Amid Decline in Shipment Volumes; Provides Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRP Q1 Profit, Revenue Fall Amid Decline in Shipment Volumes; Provides Outlook
May 31, 2024 4:15 AM

06:49 AM EDT, 05/31/2024 (MT Newswires) -- BRP (DOO.TO) on Friday reported a drop in first-quarter profit and revenue amid a decline in shipment volumes as the company focused on reducing network inventory levels.

The Canadian manufacturer of snowmobiles, all-terrain vehicles, side by sides, motorcycles, and personal watercraft, on Friday reported fiscal first-quarter normalized net income of $72.5 million, or $0.95 per diluted share, down from $192 million, or $2.38 per diluted share, a year earlier. Analysts polled by Capital IQ expected $0.94.

Revenue for the fiscal first quarter ended April 30 fell to $2.03 billion from $2.43 billion in the year-ago quarter. Analysts surveyed by Capital IQ expected $2.01 billion.

For fiscal year 2025, the company is expecting revenues of $8.6 billion to $8.9 billion. Analysts surveyed by Capital IQ are expecting $9.33 billion.

BRP is expecting normalized earnings for fiscal 2025 of $6 to $7 per diluted share. Analysts polled by Capital IQ are estimating $7.80. Normalized Ebitda for fiscal 2025 is expected to be $1.23 billion to $1.33 billion. For the second quarter of this year, BRP is expecting normalized Ebitda to be down about 25% compared with the first quarter.

The company's board maintained a quarterly dividend of $0.21 per share for holders of its multiple voting shares and subordinate voting shares. The dividend will be paid on July 12 to shareholders of record at the close of business on June 28.

BRP was down 1.5% in Canada yesterday and dropped 6% in early premarket U.S. trading on Friday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Amazon Looking to Spend $150 Billion on Data Centers
Market Chatter: Amazon Looking to Spend $150 Billion on Data Centers
Mar 28, 2024
08:34 AM EDT, 03/28/2024 (MT Newswires) -- Amazon.com ( AMZN ) plans to spend nearly $150 billion on data centers over the coming 15 years to meet the increased demand for artificial intelligence applications and other digital services, Bloomberg reported Thursday. We're expanding capacity quite significantly, said Kevin Miller, an Amazon Web Services vice president overseeing the company's data centers,...
Update: Market Chatter: JPMorgan Names Rita Chan, Alan Ho as Co-Senior Country Officers for China
Update: Market Chatter: JPMorgan Names Rita Chan, Alan Ho as Co-Senior Country Officers for China
Mar 28, 2024
08:32 AM EDT, 03/28/2024 (MT Newswires) -- (Updates with the company's response in the second paragraph.) JPMorgan ( JPM ) has appointed Rita Chan and Alan Ho as co-senior country officers for China, starting April 1, Reuters reported Thursday, citing an internal memo. A JPMorgan ( JPM ) spokesman confirmed the accuracy of the report in an email to MT...
SilverBow Resources rejects Kimmeridge's $2.1 billion takeover offer
SilverBow Resources rejects Kimmeridge's $2.1 billion takeover offer
Mar 28, 2024
March 28 (Reuters) - SilverBow Resources ( SBOW ) said on Thursday it has rejected largest shareholder Kimmeridge Energy Management's latest offer that valued the oil and gas producer at $2.1 billion, including debt, in the latest rebuff of the asset manager's efforts. ...
Gilead Sciences Signs Exclusive Development, Commercialization License for Xilio's Tumor-Activated IL-12
Gilead Sciences Signs Exclusive Development, Commercialization License for Xilio's Tumor-Activated IL-12
Mar 28, 2024
08:34 AM EDT, 03/28/2024 (MT Newswires) -- Gilead Sciences ( GILD ) and Xilio Therapeutics ( XLO ) said Thursday they have entered an exclusive license agreement for Gilead to develop and commercialize Xilio's phase 1 tumor-activated IL-12 molecule dubbed XTX301. Under the terms of the deal, Gilead will pay Xilio $43.5 million upfront, which includes $30 million in cash...
Copyright 2023-2026 - www.financetom.com All Rights Reserved